Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboprost tromethamine
Drug ID BADD_D00366
Description A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Indications and Usage For aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00429
KEGG ID D00682
MeSH ID C062843
PubChem ID 5281074
TTD Drug ID D07PCI
NDC Product Code 68245-0016; 43598-917; 65219-579; 55150-459; 62227-023; 82231-103; 71839-137; 70512-859; 81298-5010; 65145-132; 54893-0023; 0009-0856; 69784-240; 70121-1680; 62332-777; 43598-698; 43598-919
UNII U4526F86FJ
Synonyms carboprost tromethamine | carboprost trometamol | 15-methylprostaglandin F2alpha-tromethamine | Hemabate | Prostin M-15
Chemical Information
Molecular Formula C25H47NO8
CAS Registry Number 58551-69-2
SMILES CCCCCC(C)(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye pain06.08.03.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastrointestinal disorder07.11.01.0010.000061%Not Available
Gastrointestinal pain07.01.05.0050.000041%
Glaucoma06.03.01.0020.000041%
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Headache17.14.01.0010.000163%
Hiccups22.12.01.001; 07.01.06.009--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000041%
Hypertension24.08.02.0010.000081%
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Injection site bruising23.03.11.015; 12.07.03.042; 08.02.03.042; 24.07.06.0170.000207%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.000228%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.000207%Not Available
Injection site rash12.07.03.032; 08.02.03.032; 23.03.13.0100.000061%Not Available
Injection site urticaria23.04.02.003; 12.07.03.029; 10.01.06.003; 08.02.03.0290.000138%Not Available
Lethargy19.04.04.004; 08.01.01.008; 17.02.04.003--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.0010.000264%
Nervousness19.06.02.003--Not Available
Palpitations02.11.04.0120.000081%
Paraesthesia23.03.03.094; 17.02.06.005--
Placental disorder18.05.02.001--Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009--
Pruritus23.03.12.0010.000102%
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.0030.000041%
Rash23.03.13.0010.000102%Not Available
Respiratory distress22.02.01.012--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages